Dr. Pedro C Barata, MD MSc FACP joins the prestigious faculty lineup at the first annual #WorldGU24 this August. Explore the full faculty list and register for this 2-day #CME meeting in New York. ➡️ hubs.ly/Q02s9Z-Y0 #GUcancer

Eagerly awaiting data from CM-274 at #EAU24 Adjuvant NIVOLUMAB showing improved OS in ITT and PD-L1 ≥1% urothelial cancers 🌟🌟🌟
#EAU24 #Oncology
Matt Galsky Tom Powles OncoAlert
Niklas Klümper Uromigos

The first published manuscript of the 2024 ASCO Educational Book is online now! We'll be publishing them in real time online in the weeks leading up to the annual meeting. #ASCO24 ASCOPres Pedro C Barata, MD MSc FACP Hope Rugo

the entire #HealthcareUnfiltered video with Pedro C Barata, MD MSc FACP on ASCO #GU24 top clinical data is right here.

Check it out, and don't forget to subscribe to the podcast, review it, and rate it.

Update on biomarkers in #RenalCellCarcinoma . David Braun Yale Cancer Center joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss this evolving landscape emphasizing the transition from histological analysis to advanced techniques like genomics and transcriptomics. #WatchNow > bit.ly/4a9mJBq

Today, ⁦Pedro C Barata, MD MSc FACP⁩ on #HealthcareUnfiltered dissects ⁦ASCO⁩ #GU24 top clinical data & how they affect practice.

A must listen to all practicing oncologists & fellows.

A clip below and a pod link here. Wait until he styles the T-shirt.

podcasts.apple.com/us/podcast/hea…

Targeted #KidneyCancer therapy sparks hope for tough-to-treat pts. Dan George Duke Cancer joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to unpack insights from the #EVEREST trial, exploring mTOR inhibitor everolimus in adjuvant therapy for HR #KCa post-nephrectomy > bit.ly/3RmiRVH

Beautiful message from Dr. Kimryn Rathmell as we kick off #kidneycancer Awareness Month!

📷Super proud of my better half Tian Zhang, MD, MHS in taking this important leadership role. I am biased but UTSW Simmons Cancer Center definitely made the right choice!

Here is more info on the trial, accruing at multiple sites with a great team of collaborators! #OPTICRCC #kidneycancer
Pedro C Barata, MD MSc FACP Sumanta K. Pal, MD, FASCO Moshe Ornstein MD Tian Zhang, MD, MHS Yu-Wei Chen, MD, MS Nataliya Mar Brian Rini, MD Katy Beckermann Vanderbilt Hem / Onc Vanderbilt-Ingram Cancer Center
classic.clinicaltrials.gov/ct2/show/NCT05…

Practice-changing news from #GU24 : KEYNOTE-564 data support adjuvant pembro as a standard of care after surgery for patients with ccRCC at higher risk for recurrence: brnw.ch/21wGrP1 #ASCODailyNews Toni Choueiri, MD Pedro C Barata, MD MSc FACP

Roger Li Pedro C Barata, MD MSc FACP Andrea Apolo, M.D. Jim Hu Society of Urologic Oncology YUO ASCO OncoAlert UroToday.com P. Barata great presentation on RCC as always!

🎙️Listen to Assoc. Prof. Barata’s (Pedro C Barata, MD MSc FACP) expert insights on the KEYNOTE-564 & CheckMate-914 trial results, and #KidneyCancer treatment strategies.

Our UROONCO RCC chief editor Dr. Carmen Mir (@carme_mir1) had plenty of questions for him in this #EAUPodcast interview. 👇

Drs. Pedro Barata (Pedro C Barata, MD MSc FACP) and Christopher Wallis (@WallisCJD) discussed the efficacy of #pembrolizumab / #lenvatinib and how this IO/TKI approach compares to other frontline treatment strategies for advanced #RCC at #GU24 . Watch now: buff.ly/3SIQItG

ASCO GU24 special #EAUPodcast : Assoc. Prof. Pedro C Barata, MD MSc FACP discusses the latest KEYNOTE-564 results with Carme Mir. 🗨️'First study to show a statistically significant clinically meaningful OS improvement with an adjuvant therapy in #KidneyCancer .'
Listen🎧 ow.ly/QBby50QwGHL

Please join us Monday, 2/5 at 5:00PM EST for highlights from #GU24 with talks from Dr. Cheryl Lee, Andrea Apolo, M.D., Jim Hu, and Pedro C Barata, MD MSc FACP

Society of Urologic Oncology YUO ASCO OncoAlert UroToday.com

SUO Education Committee Webinar - GU ASCO Update conta.cc/3HQ6gpe

Bispecific antibody inhibiting PD-1 and CTLA-4 demonstrates effectiveness against advanced #KidneyCancer in early study. Martin Voss Memorial Sloan Kettering Cancer Center joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss volrustomig, the effects, abilities, and ongoing trials in this space > bit.ly/3H6Ekxf

Pedro C Barata, MD MSc FACP recaps his excellent discussion on adjuvant therapy in RCC from #ASCOGU24 including the pembro OS data

spotifyanchor-web.app.link/e/lAro4rYuMGb

ASCO #GU24 #Discussant : Adjuvant treatment for #RCC – Strategies on how to optimize patient selection for the new Standard of Care. Presentation by Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3vPHnrc

Wrapping up #gu24 with the Case Comp Cancer Ctr GU squad . Collaborating with this crew every day is an absolute joy! Adam Calaway Jason Brown Pedro C Barata, MD MSc FACP